Oncopeptides Overview

  • Founded
  • 2000
Founded
  • Status
  • Public
  • Employees
  • 154
Employees
  • Stock Symbol
  • ONCO
Stock Symbol
  • Share Price
  • $14.06
  • (As of Thursday Closing)

Oncopeptides General Information

Description

Oncopeptides AB is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen (Ygalo), a peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment of hematological cancers and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with melflufen compared with established alternative drugs for patients with multiple myeloma. Melflufen will potentially provide physicians with a new treatment option for patients suffering from this serious disease.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
STO
Primary Office
  • Västra Trädgårdsgatan 15
  • 111 53 Stockholm
  • Sweden
+46 08-615 00 00

Oncopeptides Timeline

2017201820192020
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncopeptides Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$14.06 $14.00 $7.49 - $16.21 $864M 61.5M 293K -$1.20

Oncopeptides Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 802,884 637,490 589,588 331,399
Revenue 0 0 0 0
EBITDA (117,143) (77,693) (47,192) (28,941)
Net Income (117,455) (78,312) (47,249) (28,972)
Total Assets 111,658 106,259 43,799 58,610
Total Debt 0 711 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Oncopeptides Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Oncopeptides‘s full profile, request access.

Request a free trial

Oncopeptides Executive Team (19)

Name Title Board Seat Contact Info
Jakob Lindberg MD Chief Scientific Officer
Paula Boultbee Chief Commercial Officer
Johan Harmenberg Ph.D Chief Medical Officer
Anders Martin-Löf Chief Financial Officer
Eva Nordström Vice President & Chief Operating Officer
You’re viewing 5 of 19 executive team members. Get the full list »

Oncopeptides Board Members (12)

Name Representing Role Since
Brian Stuglik Self Board Member 000 0000
Cecilia Wennborg Self Board Member 000 0000
Jarl Jungnelius Ph.D Self Board Member 000 0000
Jennifer Jackson Ph.D Self Board Member 000 0000
Jonas Brambeck Ph.D Industrifonden Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Oncopeptides Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oncopeptides Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Oncopeptides‘s full profile, request access.

Request a free trial